NEWS

Yiming Onco bispecific antibody IMM2902 approved for clinical

Release time:

2021-07-02 16:53

Yiming Onco bispecific antibodyIMM2902Approved Clinical

Yiming Onco was founded in2015In 2010, he focused on the development of anti-tumor immunotherapy products, including bispecific antibodies, new recombinant proteins, andTANKTMCell therapy, etc. The common feature of these products is to stimulate the patient's own immune system to exert anti-tumor effects, and ultimately inhibit the continued growth of tumor cells, reverse the resulting series of malignant symptoms, so that patients gradually return to a healthy body state.

6Month30day,The companyAnnounced that China's State Drug Administration(NMPA)Approve itsCD47x HER2double target antibody-RECEPTOR RECOMBINANT PROTEIN DRUGIMM2902Conduct clinical trials for indicationsHER2expression of breast cancer, gastric cancer, lung cancer and other solid tumors.

CD47It is highly expressed on the surface of a variety of tumors and belongs to a pan-tumor target, which is considered by some in the industry to be the next one.“PD-1”Star target.CD47Widely expressed on human cells, with macrophage surfaceSIRPareceptor binding will express“Don't eat me”Signal. However, cunning tumor cells will be highly expressedCD47and escape being engulfed by macrophages. TargetingCD47Antibodies can block tumor cells“Don't eat me”signals, activating“Eat me.”signal, thereby prompting macrophages to phagocytize tumor cells.

IMM2902The project is based on Yiming Onco.“mAb-Trap”A new generation of biantibody drug candidates developed on the technology platform with global independent intellectual property rights, targeting immunomodulatory targets.CD47withHER2, by acceleratingHER2inhibition of tumor cell growth by blocking the endocytosis and degradation“Don't eat me”Signal and Activation“Eat me.”signal to stimulate macrophage phagocytosis of tumor cells, and the phagocytosed tumor antigen presentedTcells, thus exerting a powerful tumor immunotherapy effect.

Founder of Yiming Angke CompanyDr. Tien said,IMM2902is aimedCD47andHER2of dual target-specific molecules,HER2The high affinity activity allows the drug to preferentially bind to tumor cells, while retaining non-binding to human red blood cells and avoiding“Antigenic sink”and other characteristics, greatly enhancing the dual-target tumor-specific synergistic effect.

in addition,Yiming AngkeofThe other two are based onCD47Targeted new drugs have also entered the clinical research phase:A paragraphIMM01It is a new generationCD47Targeted immune checkpoint inhibitors,Another paragraphIMM0306It is a target.CD47andCD20of the antibody-Receptor Recombinant Protein.Dr. Tien also saidYiming Onco has been committed to the research and development of anti-tumor drugs to create new immunomodulatory targets, and several of the company's dual-target-specific protein drugs have shown good prospects for development. Yiming Onco will continue to deepen the anti-tumor field, accelerate the pace of research and development, and develop one safe and efficient anti-tumor drug after another, so as to bring good news to the majority of cancer patients. We look forward to the smooth progress of these new drug clinical studies and the early benefit of patients.

Antibody, tumor, cell, cd47,her2, drug, specificity, signal, expression